Picture of Vertex Pharmaceuticals logo

VRTX Vertex Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Vertex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue2,4893,0484,1636,2067,574
Cost of Revenue
Gross Profit2,2162,6383,6155,4696,670
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses2,3652,4122,9653,3494,792
Operating Profit1236351,1982,8562,782
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-15.76001,3953,1172,730
Provision for Income Taxes
Net Income After Taxes91.65271,1772,7122,342
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income2632,0971,1772,7122,342
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income2632,0961,1772,7122,342
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS1.732.174.5110.39.01

Or unlock with your email

Or unlock with your email